Navigation Links
Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
Date:5/21/2009

ience," OAB is disabling and associated with a marked decrease in health-related quality of life as well as higher rates of depression. The disease affects both men and women however, women experience more severe symptoms earlier in life.

In addition to GELNIQUE, Watson recently launched RAPAFLO(TM) (silodosin), the Company's new alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), which offers rapid relief and has an exceptional safety profile. The Company also has submitted a New Drug Application for its 6-month formulation of TRELSTAR(R) (triptorelin pamoate), a luteinizing hormone releasing hormone (LHRH) agonist for the palliative treatment of advanced prostate cancer. Watson anticipates that FDA will take action on this application in the third quarter 2009.

About GELNIQUE

GELNIQUE is a quick-drying, clear and colorless, fragrance-free hydroalcoholic gel containing oxybutynin chloride, an antispasmodic antimuscarinic agent. Applied once daily to the thigh, abdomen, upper arm or shoulder, one-gram (approx. 1 mL) of GELNIQUE gel 10% delivers a consistent dose of oxybutynin through the skin over a 24-hour period, providing strong efficacy with excellent tolerability.

Because the active ingredient in GELNIQUE is delivered transdermally, it is not metabolized in the same way as orally administered oxybutynin. It bypasses fist-pass metabolism, which reduces the formation of the N-desethyloxybutynin metabolite (N-DEO), which may be linked to unwanted side effects such as dry mouth and constipation. In clinical trials, GELNIQUE users reported low levels of dry mouth (6.9%) and constipation (1.3%).

In a Phase 3, 12-week trial, one-gram, once-daily GELNIQUE was superior to placebo at relieving OAB symptoms, including a reduction in incontinence episodes and urinary frequency, and an increase in urine void volume. The treatment
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Watson-Marlow Releases Informative Video Featuring Showcased High Purity Pumps, Tubing and Fillers at Interphex 2009
2. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
3. Watson Files FDA Applications for Generic Mucinex(R)
4. Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting
5. Companies Continue To Add Wellness Programs, Watson Wyatt/National Business Group On Health Survey Finds
6. Mark G. Watson Named Executive Director of Radiological Society of North America
7. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
8. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
9. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
10. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
11. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... ... 50 will emanate from Levi’s Stadium in Santa Clara, CA on Sunday, February 7, ... the two weeks that separate the conference championships and the Super Bowl, there is plenty ... mark the 50th time it has been held and the festivities will take place at ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... five new industry players to know in predictive health analytics , Jvion ... learning technologies. The firm creates predictive software that targets patient and population level ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics ... this week. Zeltiq Aesthetics released this new applicator in the United States as ... treating the outer thighs. The original applicator required a 2 hour treatment time. ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Insurance Group, Inc. has re-branded their social media profiles to better connect with ... for consumers to communicate, find information, share insights and opinions. The Rally Insurance ...
(Date:7/31/2015)... ... , ... Ticket Down is a reliable source of authentic Hamilton tickets ... refreshing show on Broadway, look no further than Hamilton. This American musical is critically ... Circle Award, Drama Desk Award, Lucille Lortel Award, and New York Drama Critics’ Award. ...
Breaking Medicine News(10 mins):Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7
... Beckman Coulter, Inc. (NYSE: BEC ... products that simplify, automate, and innovate complex biomedical ... vice president of strategy, will present at the ... 2009 at 11:00 a.m. (ET).(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ...
... cancer patients in a clinical trial were not concerned ... side effects, such as infection, pain and nausea and ... joining the clinical trial, according to a study led ... few patients reported substantial worry about drug costs, still ...
... Vitamin D intake in 3-ounce servingsMONTEREY, Calif., May 29 ... United States Department of Agriculture (USDA), Monterey Mushrooms, Inc. ... when mushrooms are exposed to light. Mushrooms respond ... the sun rays into Vitamin D. By exposing ...
... Pediatric Unit Provides Family Environment and Long-Term Care to Youth ... Center marks its 125th anniversary with the launch of ... welcomes families and simulates a home environment for long-term patients ... support that is difficult to provide in a home, group ...
... less likely than walking or running as kids age, researchers ... get older, many adolescents become less physically active and are ... a new study finds. , Researchers asked secondary school students ... five years and found that 94 percent of the students ...
... can be powerful, study says, , , FRIDAY, May 29 (HealthDay ... can help people facing the same fate make more informed ... end of their life, a new study suggests. , "Medicine ... medical care at the end of life," said the study,s ...
Cached Medicine News:Health News:1 in 10 advanced colon cancer patients worry about prescription drug costs 2Health News:Monterey Mushrooms Launches Vitamin D Enriched Sun Grill-A-Bella and White Mushrooms 2Health News:Home At HSC 2Health News:Teens Likely to Trade Team Sports for Individual Exercise 2Health News:Video May Help People Make End-of-Life Choices 2Health News:Video May Help People Make End-of-Life Choices 3
(Date:7/31/2015)... , July 31, 2015  Xcelience, a ... that it has made a structured cash investment ... company specializing in milling, micronization and powder size ... help grow Powdersize,s business while simultaneously adding a ... Xcelience,s portfolio of capabilities. "As ...
(Date:7/31/2015)... Pa. , July 31, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... the closing of its previously announced underwritten public ... at a public offering price of $11.25 per ... offering included 1,000,000 shares issued upon the exercise ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... 2011 The U.S. Chamber of Commerce has ... CEO Mark Merritt into its elite "Association Committee ... executives. Committee members recommend Chamber policy ... collaboration, and encourage involvement in Chamber activities.  The ...
... Calif., May 17, 2011 VIVUS, Inc. ... results from a pivotal phase 3 open-label clinical trial ... avanafil for the treatment of erectile dysfunction (ED) were ... Urological Association in Washington, D.C.  Laurence Belkoff, DO, FACOS, ...
Cached Medicine Technology:Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting 2Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting 3Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting 4Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting 5
... confirmed Atriums superior biocompatibility and strength ... hernia repair. These same studies indicate ... hernia mesh can result in a ... when Atrium first introduced thin wall ...
... Repair Company, we recognize that there are ... tissue in-growth between the prosthesis and the ... Like all the products in Bards complete ... clinically proven, versatile repair.,The Reconix Patch is ...
... In applications such as laparoscopic ... reconstruction, surgeons require a surgical biomaterial ... incorporation.,GORE MYCROMESH Biomaterial provides the answer ... soft tissue reconstructions. Made from strong, ...
... CompanySM is pleased to announce the latest ... Composix E/X mesh.,When Bard Composix mesh was ... ventral hernia repair prosthesis that combined two ... ePTFE, in one product. Bard Composix E/X ...
Medicine Products: